Highlights
-
Revenue of $16.1 million – up 7.8% constant currency
-
U.S. open heart revenue, including AtriClip, of $9.3 million – up 10.6%
-
International sales of $3.8 million – up 16.7% constant currency
WEST CHESTER, Ohio--(BUSINESS WIRE)--Nov. 1, 2012--
AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in
cardiac surgical ablation systems for the treatment of atrial
fibrillation, or AF, and systems for the exclusion of the left atrial
appendage, today announced financial results for the third quarter of
2012.
Revenue for third quarter 2012 was $16.1 million, reflecting 6.0% growth
(7.8% growth constant currency) over the third quarter of 2011. Revenue
from U.S. product sales was $12.4 million, reflecting growth of 5.1%,
and revenue from product sales to international customers was $3.8
million, reflecting growth of 9.0% or 16.7% on a constant currency basis.
“We are pleased with our performance in the third quarter which saw
continued growth in domestic product sales, driven by US open heart
revenue, and ongoing strength in international markets. Our management
and sales teams have remained steadfast in their commitment to executing
our strategy – to increase market share and penetration in open
procedures, support our MIS business and expand our international
presence,” said Dick Johnston, Chairman of AtriCure’s Board of
Directors. “We are also pleased to announce today that Mike Carrel has
joined AtriCure as President and Chief Executive Officer, effective
November 1, 2012. We believe Mike will be instrumental in leading the
company to capitalize on our AF approval, the strength of our product
portfolio, ongoing marketing and education initiatives and clinical
programs to drive shareholder value.”
Third Quarter Financial Results
Revenue for the third quarter of 2012 was $16.1 million, an increase of
$0.9 million or 6.0% compared to third quarter 2011 revenue. Domestic
revenue increased 5.1% to $12.4 million, including $1.6 million in sales
of the AtriClip system. International revenue was $3.8 million, an
increase of $0.3 million or 9.0% (16.7% on a constant currency basis)
when compared to $3.5 million for the third quarter of 2011.
International revenue growth was driven primarily by an increase in
sales in European markets.
Gross profit for the third quarter of 2012 was $11.5 million compared to
$11.1 million for the third quarter of 2011. Gross margin for the third
quarter of 2012 was 71.6% compared to 72.8% for the third quarter of
2011. The decrease in gross margin was due primarily to our investment
in manufacturing and quality systems to transition and maintain the
manufacturing of PMA approved products and to support our expanding
operations.
Operating expenses for the third quarter of 2012 increased 14.7%, or
$1.8 million, to $14.1 million from $12.3 million for the third quarter
of 2011. The increase in operating expenses was driven primarily by a
combination of increased selling, marketing and training expenses as
well as non-recurring severance charges in the quarter.
Loss from operations for the third quarter of 2012 was $2.5 million
compared to $1.2 million for the third quarter of 2011. Adjusted EBITDA,
a non-GAAP measure, was a loss of $1.0 million for the third quarter of
2012. Net loss per share was $0.16 for the third quarter of 2012 and
$0.07 for the third quarter of 2011.
Cash, cash equivalents and investments were $13.0 million at September
30, 2012, and cash used in operations during the third quarter of 2012
was $0.5 million.
Conference Call
AtriCure will host a conference call at 4:30 p.m. Eastern Time on
Thursday, November 1, 2012 to discuss its third quarter 2012 financial
results. A live webcast of the conference call will be available online
from the investor relations page of AtriCure’s corporate website at www.atricure.com.
Pre-registration is available and recommended for this call at the
following URL: https://www.theconferencingservice.com/prereg/key.process?key=PJLC7TYK6
You may also access this call through an operator by calling (888)
680-0893 for domestic callers and (617) 213-4859 for international
callers at least 15 minutes prior to the call start time using
reservation code 74114405.
The webcast will be available on AtriCure’s website and a telephonic
replay of the call will also be available through December 3, 2012. The
replay dial-in numbers are (888) 286-8010 for domestic callers and (617)
801-6888 for international callers. The reservation code is 96443161.
About AtriCure, Inc.
AtriCure, Inc. is a medical device company and a leader in developing,
manufacturing and selling innovative cardiac surgical ablation systems
designed to create precise lesions, or scars, in cardiac, or heart,
tissue for the treatment of atrial fibrillation, or AF, and systems for
the exclusion of the left atrial appendage. The Company believes
cardiothoracic surgeons are adopting its ablation products for the
treatment of AF during concomitant open-heart surgical procedures and
sole-therapy minimally invasive procedures. AF affects more than 5.5
million people worldwide and predisposes them to a five-fold increased
risk of stroke. The FDA has not cleared or approved certain AtriCure
products for the treatment of AF or a reduction in the risk of stroke.
Forward-Looking Statements
This press release contains “forward-looking statements” within the
meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include statements that address activities,
events or developments that AtriCure expects, believes or anticipates
will or may occur in the future, such as earnings estimates, other
predictions of financial performance, launches by AtriCure of new
products and market acceptance of AtriCure’s products. Forward-looking
statements are based on AtriCure’s experience and perception of current
conditions, trends, expected future developments and other factors it
believes are appropriate under the circumstances and are subject to
numerous risks and uncertainties, many of which are beyond AtriCure’s
control. These risks and uncertainties include the rate and degree of
market acceptance of AtriCure’s products, AtriCure’s ability to develop
and market new and enhanced products, the timing of and ability to
obtain and maintain regulatory clearances and approvals for its
products, the timing of and ability to obtain reimbursement of
procedures utilizing AtriCure’s products, competition from existing and
new products and procedures or AtriCure’s ability to effectively react
to other risks and uncertainties described from time to time in
AtriCure’s SEC filings, such as fluctuation of quarterly financial
results, reliance on third party manufacturers and suppliers, litigation
or other proceedings, government regulation and stock price volatility.
AtriCure does not guarantee any forward-looking statement, and actual
results may differ materially from those projected. AtriCure undertakes
no obligation to publicly update any forward-looking statement, whether
as a result of new information, future events or otherwise.
Use of Non-GAAP Financial Measures
To supplement AtriCure’s condensed consolidated financial statements
prepared in accordance with U.S. generally accepted accounting
principles, or GAAP, AtriCure uses certain non-GAAP financial measures
in this release as supplemental financial metrics. Non-GAAP financial
measures provide an indication of performance excluding certain items.
Our management believes that in order to properly understand short-term
and long-term financial trends, investors may wish to consider the
impact of these excluded items in addition to GAAP measures. The
excluded items vary in frequency and/or impact on our continuing
operations and our management believes that the excluded items are
typically not reflective of our ongoing core business operations.
Further, management uses results of operations before these excluded
items as a basis for its strategic planning. The non-GAAP financial
measures used by AtriCure may not be the same or calculated the same as
those used by other companies. Reconciliations of the non-GAAP financial
measures used in this release to the most comparable GAAP measures for
the respective periods can be found in tables later in this release.
Non-GAAP financial measures have limitations as analytical tools and
should not be considered in isolation or as a substitute for AtriCure’s
financial results prepared and reported in accordance with GAAP.
|
|
|
ATRICURE, INC.
|
|
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
|
|
(In Thousands, Except Per Share Amounts)
|
|
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30,
|
|
|
Nine Months Ended September 30,
|
|
|
|
2012
|
|
2011
|
|
|
2012
|
|
2011
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue
|
|
$
|
16,139
|
|
|
$
|
15,222
|
|
|
|
$
|
51,883
|
|
|
$
|
47,639
|
|
|
Cost of revenue
|
|
|
4,590
|
|
|
|
4,137
|
|
|
|
|
14,871
|
|
|
|
12,383
|
|
|
Gross profit
|
|
|
11,549
|
|
|
|
11,085
|
|
|
|
|
37,012
|
|
|
|
35,256
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses:
|
|
|
|
|
|
|
|
|
|
|
Research and development expenses
|
|
|
2,905
|
|
|
|
3,069
|
|
|
|
|
9,180
|
|
|
|
8,893
|
|
|
Selling, general and administrative expenses
|
|
|
11,173
|
|
|
|
9,207
|
|
|
|
|
33,178
|
|
|
|
29,399
|
|
|
Total operating expenses
|
|
|
14,078
|
|
|
|
12,276
|
|
|
|
|
42,358
|
|
|
|
38,292
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from operations
|
|
|
(2,529
|
)
|
|
|
(1,191
|
)
|
|
|
|
(5,346
|
)
|
|
|
(3,036
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
Other (expense) income
|
|
|
(27
|
)
|
|
|
47
|
|
|
|
|
(148
|
)
|
|
|
(314
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss before income tax expense
|
|
|
(2,556
|
)
|
|
|
(1,144
|
)
|
|
|
|
(5,494
|
)
|
|
|
(3,350
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
Income tax expense
|
|
|
(11
|
)
|
|
|
(12
|
)
|
|
|
|
(20
|
)
|
|
|
(26
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss
|
|
$
|
(2,567
|
)
|
|
$
|
(1,156
|
)
|
|
|
$
|
(5,514
|
)
|
|
$
|
(3,376
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted net loss per share
|
|
$
|
(0.16
|
)
|
|
$
|
(0.07
|
)
|
|
|
$
|
(0.34
|
)
|
|
$
|
(0.22
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares used in computing net loss per common
share:
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted
|
|
|
16,278
|
|
|
|
15,811
|
|
|
|
|
16,143
|
|
|
|
15,608
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ATRICURE, INC.
|
|
CONDENSED CONSOLIDATED BALANCE SHEETS
|
|
(In Thousands)
|
|
(Unaudited)
|
|
|
|
|
|
|
|
|
|
September 30,
|
|
December 31,
|
|
|
|
2012
|
|
2011
|
|
Assets
|
|
|
|
|
|
|
|
|
|
|
|
Current assets:
|
|
|
|
|
|
Cash, cash equivalents and short-term investments
|
|
$
|
13,048
|
|
|
$
|
14,183
|
|
|
Accounts receivable
|
|
|
9,391
|
|
|
|
9,514
|
|
|
Inventories
|
|
|
6,878
|
|
|
|
6,563
|
|
|
Other current assets
|
|
|
802
|
|
|
|
933
|
|
|
Total current assets
|
|
|
30,119
|
|
|
|
31,193
|
|
|
|
|
|
|
|
|
Property and equipment, net
|
|
|
3,205
|
|
|
|
2,351
|
|
|
Intangible assets
|
|
|
36
|
|
|
|
45
|
|
|
Long-term investments
|
|
|
-
|
|
|
|
-
|
|
|
Other assets
|
|
|
384
|
|
|
|
270
|
|
|
Total assets
|
|
$
|
33,744
|
|
|
$
|
33,859
|
|
|
|
|
|
|
|
|
Liabilities and Stockholders' Equity
|
|
|
|
|
|
|
|
|
|
|
|
Current liabilities:
|
|
|
|
|
|
Accounts payable and accrued liabilities
|
|
$
|
9,570
|
|
|
$
|
9,266
|
|
|
Current maturities of debt and capital lease obligations
|
|
|
2,034
|
|
|
|
1,543
|
|
|
Total current liabilities
|
|
|
11,604
|
|
|
|
10,809
|
|
|
|
|
|
|
|
|
Long-term debt and capital lease obligations
|
|
|
6,866
|
|
|
|
4,926
|
|
|
Other liabilities
|
|
|
1,713
|
|
|
|
2,509
|
|
|
Total liabilities
|
|
|
20,183
|
|
|
|
18,244
|
|
|
|
|
|
|
|
|
Stockholders' equity:
|
|
|
|
|
|
Common stock
|
|
|
17
|
|
|
|
16
|
|
|
Additional paid-in capital
|
|
|
122,268
|
|
|
|
118,853
|
|
|
Other comprehensive income (loss)
|
|
|
7
|
|
|
|
(37
|
)
|
|
Accumulated deficit
|
|
|
(108,731
|
)
|
|
|
(103,217
|
)
|
|
Total stockholders' equity
|
|
|
13,561
|
|
|
|
15,615
|
|
|
|
|
|
|
|
|
Total liabilities and stockholders' equity
|
|
$
|
33,744
|
|
|
$
|
33,859
|
|
|
|
|
|
|
|
|
|
|
|
|
ATRICURE, INC.
|
|
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
|
|
(In Thousands)
|
|
(Unaudited)
|
|
|
|
|
|
|
|
Nine Months Ended September 30,
|
|
|
2012
|
|
2011
|
|
|
|
|
|
|
Cash flows from operating activities:
|
|
|
|
|
Net loss
|
$
|
(5,514
|
)
|
|
$
|
(3,376
|
)
|
|
Adjustments to reconcile net loss to net cash used in operating
activities:
|
|
|
|
|
Share-based compensation
|
|
2,941
|
|
|
|
2,249
|
|
|
Depreciation and amortization
|
|
1,520
|
|
|
|
1,492
|
|
|
Write-off of deferred financing costs and discount on long-term
debt
|
|
-
|
|
|
|
153
|
|
|
Amortization of deferred financing costs and discount on long-term
debt
|
|
81
|
|
|
|
94
|
|
|
(Gain) loss on disposal of equipment
|
|
(12
|
)
|
|
|
51
|
|
|
Amortization/accretion on investments
|
|
16
|
|
|
|
-
|
|
|
Change in allowance for doubtful accounts
|
|
(21
|
)
|
|
|
23
|
|
|
Changes in assets and liabilities
|
|
|
|
|
Accounts receivable
|
|
125
|
|
|
|
506
|
|
|
Inventories
|
|
(319
|
)
|
|
|
(880
|
)
|
|
Other current assets
|
|
122
|
|
|
|
(202
|
)
|
|
Accounts payable and accrued liabilities
|
|
(510
|
)
|
|
|
(885
|
)
|
|
Other non-current assets and liabilities
|
|
(174
|
)
|
|
|
(84
|
)
|
|
Net cash used in operating activities
|
|
(1,745
|
)
|
|
|
(859
|
)
|
|
|
|
|
|
|
Cash flows from investing activities:
|
|
|
|
|
Purchases of available-for-sale securities
|
|
(8,538
|
)
|
|
|
(12,602
|
)
|
|
Maturities of available-for-sale securities
|
|
8,100
|
|
|
|
9,156
|
|
|
Purchases of equipment
|
|
(2,372
|
)
|
|
|
(852
|
)
|
|
Net proceeds from the sale of assets
|
|
24
|
|
|
|
89
|
|
|
Net cash used in investing activities
|
|
(2,786
|
)
|
|
|
(4,209
|
)
|
|
|
|
|
|
|
Cash flows from financing activities:
|
|
|
|
|
Proceeds from borrowings of debt
|
|
10,000
|
|
|
|
7,500
|
|
|
Payments on debt and capital leases
|
|
(7,568
|
)
|
|
|
(3,661
|
)
|
|
Proceeds from stock option exercises
|
|
562
|
|
|
|
1,056
|
|
|
Payment of debt fees
|
|
(78
|
)
|
|
|
(81
|
)
|
|
Proceeds from issuance of common stock under employee stock
purchase plan
|
|
372
|
|
|
|
346
|
|
|
Shares repurchased for payment of taxes on stock awards
|
|
(372
|
)
|
|
|
(735
|
)
|
|
Net cash provided by financing activities
|
|
2,916
|
|
|
|
4,425
|
|
|
|
|
|
|
|
Effect of exchange rate changes on cash and cash equivalents
|
|
59
|
|
|
|
(156
|
)
|
|
|
|
|
|
|
Net decrease in cash and cash equivalents
|
|
(1,556
|
)
|
|
|
(799
|
)
|
|
Cash and cash equivalents - beginning of period
|
|
9,759
|
|
|
|
4,231
|
|
|
Cash and cash equivalents - end of period
|
$
|
8,203
|
|
|
$
|
3,432
|
|
|
|
|
|
|
|
|
|
|
|
ATRICURE, INC.
|
|
RECONCILIATION OF GAAP RESULTS TO NON-GAAP RESULTS
|
|
(In Thousands)
|
|
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reconciliation of Non-GAAP Adjusted Earnings (Adjusted EBITDA)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30,
|
|
|
Nine Months Ended September 30,
|
|
|
|
2012
|
|
2011
|
|
|
2012
|
|
2011
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss, as reported
|
|
$
|
(2,567
|
)
|
|
$
|
(1,156
|
)
|
|
|
$
|
(5,514
|
)
|
|
$
|
(3,376
|
)
|
|
Income tax expense
|
|
|
11
|
|
|
|
12
|
|
|
|
|
20
|
|
|
|
26
|
|
|
Other expense (income) (a)
|
|
|
27
|
|
|
|
(47
|
)
|
|
|
|
148
|
|
|
|
314
|
|
|
Depreciation and amortization expense
|
|
|
467
|
|
|
|
414
|
|
|
|
|
1,520
|
|
|
|
1,492
|
|
|
Share-based compensation expense
|
|
|
1,111
|
|
|
|
712
|
|
|
|
|
2,941
|
|
|
|
2,249
|
|
|
Non-GAAP adjusted (loss) earnings (adjusted EBITDA)
|
|
$
|
(951
|
)
|
|
$
|
(65
|
)
|
|
|
$
|
(885
|
)
|
|
$
|
705
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30,
|
|
|
Nine Months Ended September 30,
|
|
(a) Other includes:
|
|
|
2012
|
|
|
|
2011
|
|
|
|
|
2012
|
|
|
|
2011
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net interest expense
|
|
$
|
(187
|
)
|
|
$
|
(165
|
)
|
|
|
$
|
(609
|
)
|
|
$
|
(638
|
)
|
|
Grant income
|
|
|
117
|
|
|
|
85
|
|
|
|
|
379
|
|
|
|
109
|
|
|
(Loss) gain due to exchange rate fluctuation
|
|
|
(42
|
)
|
|
|
17
|
|
|
|
|
(77
|
)
|
|
|
154
|
|
|
Non-employee stock option income
|
|
|
85
|
|
|
|
110
|
|
|
|
|
159
|
|
|
|
61
|
|
|
Other (expense) income
|
|
$
|
(27
|
)
|
|
$
|
47
|
|
|
|
$
|
(148
|
)
|
|
$
|
(314
|
)
|
Source: AtriCure, Inc.
AtriCure, Inc.
Andy Wade, Vice President, Finance,
513-755-4564
awade@atricure.com
or
Investor
Relations
Westwicke Partners
Lynn Pieper, 415-202-5678
lynn.pieper@westwicke.com
|
